These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36620538)

  • 1. Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma.
    Du Z; Yin H; Zhao S; Ma Y; Sun Z; Dong B; Zhu M; Zhu C; Peng J; Yang T
    Front Oncol; 2022; 12():1062655. PubMed ID: 36620538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report.
    Yang R; Chen JX; Luo SH; Chen TT; Chen LW; Huang B
    World J Clin Cases; 2023 Feb; 11(5):1165-1174. PubMed ID: 36874416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor.
    Shao LJ; Wang HJ; Wang JR; Yuan XF; Sha Q
    Pak J Med Sci; 2022; 38(5):1243-1249. PubMed ID: 35799745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
    J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study.
    Ren X; Tian Y; Wang Z; Wang J; Li X; Yin Y; Chen R; Zhan Y; Zeng X
    BMC Urol; 2022 Aug; 22(1):128. PubMed ID: 35987640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.
    Wang Z; Wang Y; Wang S; Ran Q; Peng S; Zhang Y; Zhang J; Zhang D; Wang L; Lan W; Liu Q; Jiang J
    Ann Med Surg (Lond); 2024 Jan; 86(1):245-251. PubMed ID: 38222740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
    Cockerill PA; Knoedler JJ; Frank I; Tarrell R; Karnes RJ
    BJU Int; 2016 Mar; 117(3):456-62. PubMed ID: 25682834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.
    Huang CP; Wu CC; Shyr CR
    Cancer Immunol Immunother; 2021 May; 70(5):1419-1433. PubMed ID: 33156394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
    Daneshmand S; Brummelhuis ISG; Pohar KS; Steinberg GD; Aron M; Cutie CJ; Keegan KA; Maffeo JC; Reynolds DL; Raybold B; Chau A; Witjes JA
    Urol Oncol; 2022 Jul; 40(7):344.e1-344.e9. PubMed ID: 35431132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer.
    Breyer BN; Whitson JM; Carroll PR; Konety BR
    Urol Oncol; 2010; 28(5):510-4. PubMed ID: 19171491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
    Cao M; Ma CK; Ma J; Chen HG; Xue W
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.
    Efiloğlu Ö; Bayrak Ö; Turan T; Kazan HÖ; Çulpan M; Çakıcı MÇ; Erturhan S; Yıldırım A
    Arch Esp Urol; 2021 Nov; 74(9):875-882. PubMed ID: 34726624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
    Delto JC; Kobayashi T; Benson M; McKiernan J; Abate-Shen C
    Oncotarget; 2013 Feb; 4(2):269-76. PubMed ID: 23563166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
    Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
    Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
    Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
    Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
    Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.